MITA: CMS should weigh Dx endpoints for beta amyloid PET imaging coverage

We have a conflict on our hands regarding beta amyloid PET imaging--something that some see as an important tool to help diagnose Alzheimer's disease. Here's why: The Medical Imaging & Technology Alliance (MITA) wants the Centers for Medicare & Medicaid Services (CMS) to consider diagnostic endpoints as a basis for covering the procedure. MITA basically argues that PET imaging to search for beta amyloid plaque can aid in diagnosing cognitive dysfunction much earlier than current technology and lead to quicker treatments. But the Medicare Evidence Development and Coverage Advisory Committee, or MEDCAC, determined that there isn't enough evidence to prove that the technology can help improve health outcomes. MITA wants CMS to consider diagnostic endpoints rather than therapeutic ones when it decides whether to cover beta amyloid PET imaging. Release

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.